Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
Parkinson's disease
cost-of-illness
late-stage parkinsonism
resource utilization
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
revised:
29
12
2023
received:
10
05
2023
accepted:
02
01
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Parkinson's disease (PD) is a neurodegenerative disease that leads to progressive disability. Cost studies have mainly explored the early stages of the disease, whereas late-stage patients are underrepresented. The aim is to evaluate the resource utilization and costs of PD management in people with late-stage disease. The Care of Late-Stage Parkinsonism (CLaSP) study collected economic data from patients with late-stage PD and their caregivers in five European countries (France, Germany, the Netherlands, UK, Sweden) in a range of different settings. Patients were eligible to be included if they were in Hoehn and Yahr stage >3 in the on state or Schwab and England stage at 50% or less. In total, 592 patients met the inclusion criteria and provided information on their resource utilization. Costs were calculated from a societal perspective for a 3-month period. A least absolute shrinkage and selection operator approach was utilized to identify the most influential independent variables for explaining and predicting costs. During the 3-month period, the costs were €20,573 (France), €19,959 (Germany), €18,319 (the Netherlands), €25,649 (Sweden), and €12,156 (UK). The main contributors across sites were formal care, hospitalization, and informal care. Gender, age, duration of the disease, Unified Parkinson's Disease Rating Scale 2, the EQ-5D-3L, and the Schwab and England Scale were identified as predictors of costs. Costs in this cohort of individuals with late-stage PD were substantially higher compared to previously published data on individuals living in earlier stages of the disease. Resource utilization in the individual sites differed in part considerably among these three parameters mentioned. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease (PD) is a neurodegenerative disease that leads to progressive disability. Cost studies have mainly explored the early stages of the disease, whereas late-stage patients are underrepresented.
OBJECTIVE
OBJECTIVE
The aim is to evaluate the resource utilization and costs of PD management in people with late-stage disease.
METHODS
METHODS
The Care of Late-Stage Parkinsonism (CLaSP) study collected economic data from patients with late-stage PD and their caregivers in five European countries (France, Germany, the Netherlands, UK, Sweden) in a range of different settings. Patients were eligible to be included if they were in Hoehn and Yahr stage >3 in the on state or Schwab and England stage at 50% or less. In total, 592 patients met the inclusion criteria and provided information on their resource utilization. Costs were calculated from a societal perspective for a 3-month period. A least absolute shrinkage and selection operator approach was utilized to identify the most influential independent variables for explaining and predicting costs.
RESULTS
RESULTS
During the 3-month period, the costs were €20,573 (France), €19,959 (Germany), €18,319 (the Netherlands), €25,649 (Sweden), and €12,156 (UK). The main contributors across sites were formal care, hospitalization, and informal care. Gender, age, duration of the disease, Unified Parkinson's Disease Rating Scale 2, the EQ-5D-3L, and the Schwab and England Scale were identified as predictors of costs.
CONCLUSION
CONCLUSIONS
Costs in this cohort of individuals with late-stage PD were substantially higher compared to previously published data on individuals living in earlier stages of the disease. Resource utilization in the individual sites differed in part considerably among these three parameters mentioned. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Commission
ID : ES/L009250/1
Informations de copyright
© 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17(11):939-953. https://doi.org/10.1016/S1474-4422(18)30295-3
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-442. https://doi.org/10.1212/wnl.17.5.427
Coelho M, Ferreira J, Rosa M, Sampaio C. Treatment options for non-motor symptoms in late-stage Parkinson's disease. Expert Opin Pharmacother 2008;9(4):523-535. https://doi.org/10.1517/14656566.9.4.523
Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20(2):190-199. https://doi.org/10.1002/mds.20324
Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5(1):75-86. https://doi.org/10.1016/S1474-4422(05)70285-4
Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease? Mov Disord 2012;27(2):236-241. https://doi.org/10.1002/mds.23961
Rosqvist K, Odin P, Lorenzl S, et al. Factors associated with health-related quality of life in late-stage Parkinson's disease. Mov Disord Clin Pract 2021;8(4):563-570. https://doi.org/10.1002/mdc3.13186
Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010;25(15):2493-2500. https://doi.org/10.1002/mds.23394
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26(3):399-406. https://doi.org/10.1002/mds.23462
Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21(10):718-779. https://doi.org/10.1016/j.euroneuro.2011.08.008
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Drug and treatment costs in Parkinson's disease patients in Sweden. Acta Neurol Scand 2012;125(2):142-147. https://doi.org/10.1111/j.1600-0404.2011.01517.x
LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziégler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16(1):59-69. https://doi.org/10.2165/00019053-199916010-00006
Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002;17(6):1213-1220. https://doi.org/10.1002/mds.10262
Dodel RC, Singer M, Köhne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14(3):299-312. https://doi.org/10.2165/00019053-199814030-00006
McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson's disease. Mov Disord 2007;22(6):804-812. https://doi.org/10.1002/mds.21360
Winter Y, Balzer-Geldsetzer M, von Campenhausen S, et al. Trends in resource utilization for Parkinson's disease in Germany. J Neurol Sci 2010;294(1-2):18-22. https://doi.org/10.1016/j.jns.2010.04.011
Reese JP, Winter Y, Balzer-Geldsetzer M, et al. Morbus Parkinson: Krankheitskosten einer ambulanten Patientenkohorte. Gesundheitswesen 2011;73(1):22-29. https://doi.org/10.1055/s-0030-1247571
Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005;23(8):817-836. https://doi.org/10.2165/00019053-200523080-00007
von Campenhausen S, Winter Y, Rodrigues e Silva A, et al. Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol 2011;21(2):180-191. https://doi.org/10.1016/j.euroneuro.2010.08.002
Jennum P, Zoetmulder M, Korbo L, Kjellberg J. The health-related, social, and economic consequences of parkinsonism: a controlled national study. J Neurol 2011;258(8):1497-1506. https://doi.org/10.1007/s00415-011-5969-1
Tamás G, Gulácsi L, Bereczki D, et al. Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary. PLoS One 2014;9(9):e107704. https://doi.org/10.1371/journal.pone.0107704
Vossius C, Nilsen OB, Larsen JP. Parkinson's disease and nursing home placement: the economic impact of the need for care. Eur J Neurol 2009;16(2):194-200. https://doi.org/10.1111/j.1468-1331.2008.02380.x
Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH. Costs of drug treatment in Parkinson's disease. Mov Disord 1998;13(2):249-254. https://doi.org/10.1002/mds.870130209
Zhao YJ, Tan LCS, Li SC, et al. Economic burden of Parkinson's disease in Singapore. Eur J Neurol 2011;18(3):519-526. https://doi.org/10.1111/j.1468-1331.2010.03210.x
Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14(10):866-874.
Bach J-P, Riedel O, Klotsche J, Spottke A, Dodel R, Wittchen H-U. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease. J Neurol Sci 2012;314(1-2):41-47. https://doi.org/10.1016/j.jns.2011.11.002
Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012;8(8):435-442. https://doi.org/10.1038/nrneurol.2012.126
Valldeoriola F, Coronell C, Pont C, et al. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. Eur J Neurol 2011;18(7):980-987. https://doi.org/10.1111/j.1468-1331.2010.03320.x
Balzer-Geldsetzer M, Ferreira J, Odin P, et al. Study protocol: Care of late-stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol 2018;18(1):185. https://doi.org/10.1186/s12883-018-1184-3
Fahn S, Elton R, Members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. Recent Developments in Parkinson's Disease. Florham Park, NJ: McMellam Health Care Information; 1987:153-163.
Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson's Disease. Edinburgh: E & S Livingston; 1969:152-157.
EuroQol Research Foundation 2018. EQ-5D-3L User Guide. Basic Information on How to Use the EQ-5D-3L Instrument. https://euroqol.org/wp-content/uploads/2019/10/EQ-5D-3L-User-Guide_version-6.0.pdf. Accessed Dec 18, 2019.
Meinshausen N. Relaxed Lasso. Comput Stat Data Anal 2007;52(1):374-393. https://doi.org/10.1016/j.csda.2006.12.019
Roider J, Ngoepe A, Muenchhoff M, et al. Increased regulatory T-cell activity and enhanced T-cell homeostatic signaling in slow progressing HIV-infected children. Front Immunol 2019;10:213. https://doi.org/10.3389/fimmu.2019.00213
Koerts J, König M, Tucha L, Tucha O. Working capacity of patients with Parkinson's disease-a systematic review. Parkinsonism Relat Disord 2016;27:9-24. https://doi.org/10.1016/j.parkreldis.2016.03.017
European Statistical Office. Hospital Discharges and Length of Stay Statistics. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Hospital_discharges_and_length_of_stay_statistics. Accessed Apr 28, 2021.
Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from The Netherlands. Health Aff 2017;36(11):1987-1996. https://doi.org/10.1377/hlthaff.2017.0832
Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD. Burden of Parkinsonism: a population-based study. Mov Disord 2003;18(3):313-319. https://doi.org/10.1002/mds.10333
Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 2004;19(1):49-53. https://doi.org/10.1002/mds.10648
Das Elfte Buch Sozialgesetzbuch-Soziale Pflegeversicherung-(article 1 of the Act of 26 May 1994, BGBl. I S. 1014, 1015), as last updated by article 15 of the Act of 28 March 2021 (BGBl. I S. 591). Section 7-Pflegegeld für selbst beschaffte Pflegehilfen.
World Health Organization (WHO) Regional Office for Europe. Beds in Nursing and Residential Care Facilities, per 100000 Population. https://gateway.euro.who.int/en/indicators/hlthres_23-beds-in-nursing-and-residential-care-facilities-per-100-000/. Accessed Apr 27, 2021.
Heinzel S, Berg D, Binder S, et al. Do we need to rethink the epidemiology and healthcare utilization of Parkinson's disease in Germany? Front Neurol 2018;9:500. https://doi.org/10.3389/fneur.2018.00500
Hand A, Gray WK, Oates LL, et al. Medication use in people with late stage Parkinson's disease and parkinsonism living at home and in institutional care in north-east England: a balance of symptoms and side-effects? Parkinsonism Relat Disord 2016;32:120-123. https://doi.org/10.1016/j.parkreldis.2016.09.001
van den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ 2004;5(1):36-45. https://doi.org/10.1007/s10198-003-0189-y
Oliva-Moreno J, Trapero-Bertran M, Peña-Longobardo LM, Del Pozo-Rubio R. The valuation of informal care in cost-of-illness studies: a systematic review. Pharmacoeconomics 2017;35(3):331-345. https://doi.org/10.1007/s40273-016-0468-y
Klietz M, von Eichel H, Schnur T, et al. One year trajectory of caregiver burden in Parkinson's disease and analysis of gender-specific aspects. Brain Sci 2021;11(3):295. https://doi.org/10.3390/brainsci11030295
van Rumund A, Weerkamp N, Tissingh G, et al. Perspectives on Parkinson disease care in Dutch nursing homes. J Am Med Dir Assoc 2014;15(10):732-737. https://doi.org/10.1016/j.jamda.2014.05.009